<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29019" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sideroblastic Anemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ashorobi</surname>
            <given-names>Damilola</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chhabra</surname>
            <given-names>Anil</given-names>
          </name>
          <aff>Mary Black Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Damilola Ashorobi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anil Chhabra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29019.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Sideroblastic anemia is a type of anemia that results from abnormal utilization of iron during erythropoiesis. There are different forms of sideroblastic anemia, and all forms are defined by the presence of ring sideroblasts in the bone marrow. Ring sideroblasts are erythroid precursors containing deposits of non-heme iron in mitochondria forming a ring-like distribution around the nucleus. The iron-formed ring covers at least one-third of the nucleus rim. Sideroblastic anemia is known to cause microcytic and macrocytic anemia depending on what type of mutation led to it. Unlike iron deficiency anemia, where there is depletion of iron stores, patients with sideroblastic anemia have normal to high iron levels. Other microcytic anemias include thalassemia and anemia of chronic disease. This activity reviews the etiology, differential diagnosis, treatment and management of sideroblastic anemia and the role of the interprofessional team can improve outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of sideroblastic anemia.</p></list-item><list-item><p>Describe the difference between sideroblastic anemia and monocytic anemia.</p></list-item><list-item><p>Summarize the management and treatment of sideroblastic anemia.</p></list-item><list-item><p>Outline the role of healthcare professionals on how to manage sideroblastic anemia and improve healthcare outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29019&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29019">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29019.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sideroblastic anemia is&#x000a0;a type of anemia that results from abnormal utilization of iron during erythropoiesis.&#x000a0; There are different forms of sideroblastic anemia,&#x000a0;and all forms are defined by the presence of ring sideroblasts in the bone marrow. Ring sideroblasts are erythroid precursors containing deposits of non-heme iron in mitochondria&#x000a0;forming a ring-like distribution around the nucleus.<xref ref-type="bibr" rid="article-29019.r1">[1]</xref>&#x000a0;The iron-formed ring&#x000a0;covers at least one-third of the nucleus rim.<xref ref-type="bibr" rid="article-29019.r2">[2]</xref>&#x000a0;&#x000a0;Sideroblastic anemia is known to cause microcytic and macrocytic anemia&#x000a0;depending on what type of mutation led to it.<xref ref-type="bibr" rid="article-29019.r3">[3]</xref>&#x000a0;Unlike iron deficiency anemia, where there is depletion of iron stores, patients with sideroblastic anemia have normal to high iron levels. Other microcytic anemias include thalassemia and anemia of chronic disease.<xref ref-type="bibr" rid="article-29019.r4">[4]</xref></p>
        <p>The hemoglobin molecule contains an important protein called&#x000a0;heme.&#x000a0;Structurally, the heme contains four pyrrole rings joined by four methine bridges at the alpha position with an iron atom at the center of the ring.<xref ref-type="bibr" rid="article-29019.r5">[5]</xref> As a result of this protein molecule, the hemoglobin can perform its function of carrying oxygen to tissues. Other functions of the heme apart from the formation of hemoglobin include gas sensing, signal transduction, biological clock, circadian rhythm, and micro RNA processing.<xref ref-type="bibr" rid="article-29019.r6">[6]</xref></p>
        <p>Sideroblastic anemia is a result of abnormal erythropoiesis during heme production. 85% of heme is produced in the cytoplasm and mitochondria of the erythroblast cells while the remaining is produced in hepatocytes.<xref ref-type="bibr" rid="article-29019.r5">[5]</xref>&#x000a0; In the Shemin pathway, eight different enzymes help to coordinate heme synthesis. These enzymes include aminolevulinic acid synthase ALAS, porphobilinogen synthase, porphobilinogen deaminase, uroporphyrinogen III synthase, uroporphyrinogen decarboxylase (UROD), coproporphyrinogen oxidase (CPOX), protoporphyrinogen oxidase (PPOX), and ferrochelatase (FECH).<xref ref-type="bibr" rid="article-29019.r5">[5]</xref>&#x000a0;There are two forms of sideroblastic anemia-hereditary and acquired.</p>
        <p>This review article will discuss the etiology, epidemiology, differential diagnosis, pathophysiology, treatment and management of sideroblastic anemia.</p>
      </sec>
      <sec id="article-29019.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Sideroblastic anemia has two forms. The first, which is hereditary,&#x000a0;is caused by mutations in genes that are involved in heme synthesis, iron-sulfur cluster biogenesis, or mitochondrial metabolism.<xref ref-type="bibr" rid="article-29019.r7">[7]</xref>&#x000a0;For heme synthesis, the gene defect is on the x chromosome, forming mutations in the aminolevulinate synthase (ALAS2), adenosine triphosphate-binding cassette B7 (ABCB7) or glutaredoxin 5 (GRLX5) enzymes. Other causes include mutations in the mitochondrial transporter (SLC25A38), thiamine transporter SLC19A2, RNA modifying enzyme pseudouridine synthase (PUS1), mitochondrial tyrosyl-tRNA synthase (YARS2) and mitochondrial DNA deletions.<xref ref-type="bibr" rid="article-29019.r8">[8]</xref> The most common cause of hereditary sideroblastic anemia, however,&#x000a0;is the X-linked type caused by&#x000a0;a&#x000a0;mutation of the gene forming&#x000a0;ALAS2 enzyme.<xref ref-type="bibr" rid="article-29019.r7">[7]</xref> The ALAS2, SLC25A38, GLRX5, HSPA9, ABCB7 genes when mutated cause microcytic anemia while the mitochondria, SLC19A2, PUS1, YARS2, TRNT1 genes when mutated cause macrocytic anemia.<xref ref-type="bibr" rid="article-29019.r9">[9]</xref> The x-linked mutation causes microcytic anemia, and mitochondrial DNA deletions cause macrocytic anemia.<xref ref-type="bibr" rid="article-29019.r3">[3]</xref>Acquired sideroblastic anemia may arise from primary or secondary causes. Primary causes include&#x000a0;clonal&#x000a0;hematologic disorders which include myelodysplastic syndrome with ring sideroblast (MDS-RS) and refractory anemia with ring sideroblasts RARS.<xref ref-type="bibr" rid="article-29019.r1">[1]</xref> The former&#x000a0;is due to a mutation in the splicing factor 3b subunit 1 (SF3B1) gene which is a vital component of RNA splicing complex. Recently RARS with ring sideroblast is now classified under the MDS-RS, and the RARS with thrombocytosis is now classified as a myelodysplastic, myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T).<xref ref-type="bibr" rid="article-29019.r10">[10]</xref></p>
        <p>&#x000a0;Secondary causes are due to drugs, toxins, copper deficiency or chronic neoplastic disease.<xref ref-type="bibr" rid="article-29019.r1">[1]</xref>&#x000a0;Most common drugs that are known to cause sideroblastic anemia are antibiotics, hormones, copper-chelating agents and chemotherapy. Patnaik et al. (2017) mention that alcohol use, lead toxicity, isoniazid use also contribute to sideroblastic anemia.<xref ref-type="bibr" rid="article-29019.r11">[11]</xref></p>
      </sec>
      <sec id="article-29019.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Sideroblastic anemia is considered a rare disease.<xref ref-type="bibr" rid="article-29019.r12">[12]</xref> By definition, rare diseases affect fewer than 200,000 people in the US population. Due to the low incidence and prevalence, researchers do not have definite statistical data on the epidemiology of the disorder.</p>
      </sec>
      <sec id="article-29019.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>&#x000a0;It is important&#x000a0;to understand the pathophysiology of sideroblastic anemia,&#x000a0;heme biosynthesis, and the consequences of the defective enzyme/transport genes. Before glycine gets to join the succinyl-CoA, it is transported by the mitochondrial transporter into the mitochondria by SLC25A38.<xref ref-type="bibr" rid="article-29019.r5">[5]</xref> The first step in the synthesis of heme is the joining of glycine with succinyl-coenzyme A (succinyl-CoA) to form aminolevulinic acid (ALA) in the mitochondria. ALA is synthesized by the enzyme aminolevulinic acid synthase. ALA is then transported to the cytosol. The inability to form ALA due to a defect in the enzyme&#x000a0;ALAS2 that catalyzes the reaction&#x000a0;leads to&#x000a0;heme deficiency and sideroblastic anemia.<xref ref-type="bibr" rid="article-29019.r5">[5]</xref>&#x000a0;The ABCB7 and the GLRX5 mutations also cause heme deficiency but in a different pathway which is explained&#x000a0;below.<xref ref-type="bibr" rid="article-29019.r2">[2]</xref>&#x000a0; Just like these common mutations,&#x000a0;other genes have various functions, and their deficiencies contribute to the development of sideroblastic anemia.</p>
        <p>Hereditary sideroblastic anemia occurs when there is a defect in the gene forming some of these enzymes, genes on autosomal chromosomes and genes in mitochondria.<xref ref-type="bibr" rid="article-29019.r1">[1]</xref> The diseases caused by these gene mutations are described as non-syndromic and syndromic. Non-syndromic include X-linked sideroblastic anemia also known as sideroblastic anemia 1 (SIDBA1), SIDBA2, SIDBA3, SIDBA4 while syndromic diseases include X-linked sideroblastic anemia with ataxia (XLSA/A), Pearson's marrow-pancreas syndrome (PMPS), thiamine-responsive megaloblastic anemia (TRMA), myopathy, lactic acidosis and sideroblastic anemia(MLAS1, MLAS2), sideroblastic anemia with immunodeficiency, fevers and developmental delay (SIFD) and NDUFB11 deficiency.<xref ref-type="bibr" rid="article-29019.r9">[9]</xref>The list below shows different types of sideroblastic anemia and their different pathophysiology. All of these types are involved in heme synthesis either directly or indirectly.</p>
        <p>Non-syndromic:</p>
        <list list-type="bullet">
          <list-item>
            <p>SIDBA1 has been reported to be caused by various mutations including missense, nonsense mutations and mutations at promoter or enhancer regions.<xref ref-type="bibr" rid="article-29019.r13">[13]</xref> All these mutations show X-linked inheritance pattern. However, ALAS2 has also been reported in females due to acquired unbalanced lyonization causing heterozygous ALAS2 mutation.<xref ref-type="bibr" rid="article-29019.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>SIDBA2 is caused by a mutation in SLC25A38. Various&#x000a0;mutations have been reported including nonsense, frameshift and missense mutations.<xref ref-type="bibr" rid="article-29019.r14">[14]</xref> As mentioned above, SLC25A38 is a mitochondrial glycine transporter. It is needed to transport glycine into the mitochondria. Glycine is required to form aminolevulinic acid when joined with succinyl-CoA. When mutated, this formation is limited therefore impeding the formation of heme.</p>
          </list-item>
          <list-item>
            <p>SIDBA3 is as a result of a mutation in GLRX5. This type is very rare,&#x000a0; as only two families have been reported having it. It is caused by a homozygous mutation which interferes with the splicing of GLRX5 mRNA which reduces the function of GLRX5 which is to produce ISC in the mitochondria.<xref ref-type="bibr" rid="article-29019.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>SIDBA4 is caused by a mutation of HSPA9. Various mutations occur as in previous types including missense, nonsense, frameshift, and in-frame deletion mutations. The absence of HSPA9 in erythroid cell lines is reported to inhibit the differentiation of erythroid cells.</p>
          </list-item>
        </list>
        <p>Syndromic:</p>
        <list list-type="bullet">
          <list-item>
            <p>XLSA/A is caused by a mutation in ATP-binding cassette transporter (ABCB7). ABCB7 is involved in iron-sulfur cluster (ISC) biogenesis which helps to transport iron to the cytosol during heme production. A missense mutation in this gene would lead to X-linked sideroblastic anemia with cerebellar ataxia.<xref ref-type="bibr" rid="article-29019.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>PMPS is due to a deletion of mitochondria DNA. The mechanism causing sideroblastic anemia is unknown, but it was reported that the deletion of the mitochondria DNA causes a defect of the respiratory chain fo the mitochondria causing anemia.<xref ref-type="bibr" rid="article-29019.r15">[15]</xref> This&#x000a0;defect leads to refractory sideroblastic anemia and exocrine pancreatic insufficiency.<xref ref-type="bibr" rid="article-29019.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>TRMA is caused by a mutation of the&#x000a0; SLC19A2 gene which aids in the transport of thiamine. Thiamine is needed for the production of succinyl CoA. A defect in this protein will lead to megaloblastic anemia, diabetes mellitus, and deafness.<xref ref-type="bibr" rid="article-29019.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>MLSA1 is due to a mutation of PUS1 which helps in the translation of the respiratory chain in the mitochondria&#x000a0;and is called a missense mutation. It is not known why it causes sideroblastic anemia.<xref ref-type="bibr" rid="article-29019.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>MLSA2 is due to a mutation in the YAR2 gene which encodes mitochondrial tyrosyl tRNA synthase. The mutation of this enzyme will deplete the quantity of this enzyme. The cause of sideroblastic anemia is also unknown with this type.<xref ref-type="bibr" rid="article-29019.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>SFID is due to a mutation of the TRNT1 gene which encodes CCA-adding transfer RNA nucleotidyltransferase. The pathology of sideroblastic anemia is unknown.<xref ref-type="bibr" rid="article-29019.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>NDUFB11 deficiency is due to a deletion of 3 nucleotides in the NDUFB11 gene leading to phenylalanine deletion in the NDUFB protein causing normocytic sideroblastic anemia and lactic acidosis.<xref ref-type="bibr" rid="article-29019.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>&#x000a0;Clonal hematologic disorders such as myelodysplastic syndrome with ring sideroblast,&#x000a0; are caused by SF3B1 gene mutation. SF3B1 is one of the spliceosome proteins that are inserted into the spliceosome during the arrangement of a pre-splicing complex to become a type of U2 snRNP.<xref ref-type="bibr" rid="article-29019.r11">[11]</xref>The the function of this gene is to help join the U2 snRNP to the pre-mRNA, and it also helps in the formation of intermolecular helix between 5' end of the U2 and the 3' end of the U6 snRNAs.<xref ref-type="bibr" rid="article-29019.r11">[11]</xref></p>
      </sec>
      <sec id="article-29019.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Prussian blue staining of the peripheral smear will show the typical ring sideroblast when viewed under the microscope. This Prussian blue staining is called Perls' reaction, and there should be a minimum of 5 granules surrounding one-third of the nuclear diameter.<xref ref-type="bibr" rid="article-29019.r11">[11]</xref></p>
      </sec>
      <sec id="article-29019.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The presentation of patients with sideroblastic anemia include the common symptoms of anemia such as fatigue, malaise, shortness of breath, palpitations, and headache. Physical examination may reveal conjunctival pallor, pale skin; some may have bronze-colored skin due to iron overload. Patients with syndromic hereditary sideroblastic anemia may present with uncontrolled diabetes mellitus and deafness such as in the case of TRMA type. Hereditary types will be seen in younger patients with a family history while acquired sideroblastic anemia typically occurs in older patients with possible myelodysplastic syndrome.</p>
      </sec>
      <sec id="article-29019.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Sideroblastic anemia is diagnosed&#x000a0;by the presence of ring sideroblasts in the bone marrow. The red blood cells that contain these iron inclusions are called siderocytes.<xref ref-type="bibr" rid="article-29019.r2">[2]</xref>&#x000a0;On complete blood count, the patient's&#x000a0;mean corpuscular volume&#x000a0;is low showing microcytosis; low mean corpuscular hemoglobin and increased red blood cell distribution width.<xref ref-type="bibr" rid="article-29019.r2">[2]</xref> When the presence of ring sideroblast is confirmed using Perl's reaction, patient bone marrow should be checked for dysplasia and SF; if present, then the patient most likely has clonal hematologic disorders such as myelodysplastic syndrome. If absent, the patient either has congenital or secondary acquired sideroblastic anemia. Sometimes, patients will present with even macrocytic anemia in case of RARS.<xref ref-type="bibr" rid="article-29019.r2">[2]</xref> Genetic testing should also be considered if secondary acquired sideroblastic anemia have been ruled out, and the cause of the sideroblastic anemia is unknown.</p>
      </sec>
      <sec id="article-29019.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of sideroblastic anemia depends on severity. For patients with a mild or asymptomatic presentation, physicians can follow up in the outpatient clinic. For patients diagnosed with the X-linked sideroblastic anemia, oral pyridoxine 50-100mg/day has been proven to partially or completely correct anemia.<xref ref-type="bibr" rid="article-29019.r2">[2]</xref>&#x000a0;For patients who&#x000a0;are not responsive to pyridoxine, blood transfusion is indicated if they have severe anemia.<xref ref-type="bibr" rid="article-29019.r2">[2]</xref>&#x000a0;For patients who require chronic transfusion, iron chelation must be considered to&#x000a0;avoid iron overload. It is recommended to&#x000a0;start deferoxamine or oral chelators when&#x000a0;serum ferritin is more than 1000 ng/L.<xref ref-type="bibr" rid="article-29019.r18">[18]</xref>&#x000a0;Iron overload, if left untreated could result in unresponsiveness of pyridoxine. Therefore it is also recommended that patients with normal hemoglobin levels after pyridoxine should get phlebotomy as&#x000a0;a treatment for iron overload.<xref ref-type="bibr" rid="article-29019.r19">[19]</xref> Iron overload treatment is very important as studies have shown an improvement in anemia due to low iron levels and better responsiveness to pyridoxine.<xref ref-type="bibr" rid="article-29019.r20">[20]</xref></p>
        <p>For patients with syndromic congenital sideroblastic anemia, diabetes mellitus could develop and in such patients, tight glycemic control should be encouraged. Hypoglycemia should also be considered if blood sugar is not well controlled.</p>
        <p>For secondary acquired sideroblastic anemia caused by known drugs or toxins, such drugs should be discontinued and avoided. Since it is acquired, patient anemia will improve after the removal of the drug.</p>
        <p>Copper should be replaced in a patient with copper deficiency via nutrition.</p>
        <p>For patients with MDS/MPN-RS-T, aspirin therapy is recommended if the&#x000a0;patient has additional JAK2V617F mutation.<xref ref-type="bibr" rid="article-29019.r11">[11]</xref></p>
      </sec>
      <sec id="article-29019.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis of sideroblastic anemia includes clonal and non-clonal disorders. Clonal disorders include myelodysplastic syndromes including the MDS-RS, MDS-RS-SLD, MDS-RS-MLD and MDS/MPN-RS-T.<xref ref-type="bibr" rid="article-29019.r11">[11]</xref> Non-clonal disorders include congenital and secondary acquired such as a copper deficiency, zinc overload, lead poison, and isoniazid use.</p>
      </sec>
      <sec id="article-29019.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of sideroblastic anemia differs depending on the underlying cause. In secondary acquired sideroblastic anemia, the prognosis is good once the drugs or toxins involved are discontinued. In X-linked sideroblastic anemia, proper pyridoxine replacement and iron overload management will improve the prognosis. However, if not well managed, the prognosis&#x000a0;may&#x000a0;be poor.</p>
      </sec>
      <sec id="article-29019.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Sideroblastic anemia caused by mutations in the XLSA, GLRX5, and SLC25A38 has been reported to cause liver and systemic iron overload.<xref ref-type="bibr" rid="article-29019.r2">[2]</xref> Iron overload is a result of ineffective erythropoiesis caused by mitochondrial iron toxicity which increases iron absorption.<xref ref-type="bibr" rid="article-29019.r2">[2]</xref>&#x000a0;Iron concentrates in the liver and can eventually lead to fibrosis and cirrhosis just like in genetic hemochromatosis.</p>
        <p>In rare situations, iron could accumulate in the heart causing abnormal heart rhythm and heart failure.<xref ref-type="bibr" rid="article-29019.r2">[2]</xref></p>
      </sec>
      <sec id="article-29019.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>In congenital/hereditary sideroblastic anemia, patients are younger, and health decisions are made for them by their parents or guardians. Parents and caregivers should educate themselves about this anemia and how to manage it. Caregivers at home should ensure that patients avoid iron-rich containing food that could exacerbate more iron overload. Patients and caregivers should follow up with their hematologist for close follow up examination. Medication compliance with pyridoxine and possibly iron chelation medications is&#x000a0;important as this has been shown to help improve the healthcare outcomes in X-linked sideroblastic anemia. Balanced nutrition should be adopted to get an adequate amount of vitamins and minerals. Alcohol, isoniazid and lead poison may cause sideroblastic anemia and should be avoided in patients with hereditary anemia.<xref ref-type="bibr" rid="article-29019.r11">[11]</xref> This will prevent the acquired form of sideroblastic anemia.&#x000a0;</p>
      </sec>
      <sec id="article-29019.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Sideroblastic anemia is a rare disease. When patients are seen in primary care clinics with anemia, most are assumed to have iron deficiency anemia, which is more common. However, it is important for clinicians to keep the possibility of sideroblastic anemia in mind. It is the responsibility of the&#x000a0;primary care provider, nurse practitioner, and the internist to be able to recognize and diagnose this disease to appropriately manage the patient. Patients should be educated and be well informed about this disease as specific food or drugs can precipitate this disease. Patients with iron overload should be informed about the importance of avoiding iron-riched containing food like red meat. Also for patients taking medications that induce sideroblastic anemia, clinicians should emphasize the importance of avoiding that particular medication. The most common complication and the cause of mortality in these patients is iron overload. Clinicians and other healthcare workers should treat with iron chelating drugs in patients getting frequent transfusions. An iron overload could cause damage to various organs in the body including the liver, heart, pancreas, etc. causing more complications. More clinical research is also necessary to evaluate prognosis, and epidemiology of this disease.&#x000a0;</p>
      </sec>
      <sec id="article-29019.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29019&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29019">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/sideroblastic-anemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29019">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29019/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29019">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-29019.s16">
        <fig id="article-29019.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Sideroblastic Anemia. Contributed by&#x000a0;S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sideroblasts" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-29019.s17">
        <title>References</title>
        <ref id="article-29019.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheftel</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Prchal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ponka</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Mitochondrial iron metabolism and sideroblastic anemia.</article-title>
            <source>Acta Haematol</source>
            <year>2009</year>
            <volume>122</volume>
            <issue>2-3</issue>
            <fpage>120</fpage>
            <page-range>120-33</page-range>
            <pub-id pub-id-type="pmid">19907149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camaschella</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment.</article-title>
            <source>Semin Hematol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>371</fpage>
            <page-range>371-7</page-range>
            <pub-id pub-id-type="pmid">19786205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitzsimons</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The molecular basis of the sideroblastic anemias.</article-title>
            <source>Curr Opin Hematol</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-72</page-range>
            <pub-id pub-id-type="pmid">9372069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Massey</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Microcytic anemia. Differential diagnosis and management of iron deficiency anemia.</article-title>
            <source>Med Clin North Am</source>
            <year>1992</year>
            <month>May</month>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>549</fpage>
            <page-range>549-66</page-range>
            <pub-id pub-id-type="pmid">1578956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Severance</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hamza</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Trafficking of heme and porphyrins in metazoa.</article-title>
            <source>Chem Rev</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>109</volume>
            <issue>10</issue>
            <fpage>4596</fpage>
            <page-range>4596-616</page-range>
            <pub-id pub-id-type="pmid">19764719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Regulation of heme biosynthesis and transport in metazoa.</article-title>
            <source>Sci China Life Sci</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>58</volume>
            <issue>8</issue>
            <fpage>757</fpage>
            <page-range>757-64</page-range>
            <pub-id pub-id-type="pmid">26100009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harigae</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Biology of sideroblastic anemia].</article-title>
            <source>Rinsho Ketsueki</source>
            <year>2017</year>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>347</fpage>
            <page-range>347-352</page-range>
            <pub-id pub-id-type="pmid">28484165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujiwara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Harigae</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and genetic mutations in congenital sideroblastic anemia.</article-title>
            <source>Pediatr Int</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>675</fpage>
            <page-range>675-9</page-range>
            <pub-id pub-id-type="pmid">24003969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furuyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Iron metabolism in erythroid cells and patients with congenital sideroblastic anemia.</article-title>
            <source>Int J Hematol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>107</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-54</page-range>
            <pub-id pub-id-type="pmid">29139060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patnaik</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".</article-title>
            <source>Am J Hematol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>94</volume>
            <issue>4</issue>
            <fpage>475</fpage>
            <page-range>475-488</page-range>
            <pub-id pub-id-type="pmid">30618061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patnaik</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.</article-title>
            <source>Am J Hematol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>92</volume>
            <issue>3</issue>
            <fpage>297</fpage>
            <page-range>297-310</page-range>
            <pub-id pub-id-type="pmid">28188970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brissot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Brissot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lor&#x000e9;al</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Troadec</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Rare anemias due to genetic iron metabolism defects.</article-title>
            <source>Mutat Res Rev Mutat Res</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>777</volume>
            <fpage>52</fpage>
            <page-range>52-63</page-range>
            <pub-id pub-id-type="pmid">30115430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harigae</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Furuyama</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Hereditary sideroblastic anemia: pathophysiology and gene mutations.</article-title>
            <source>Int J Hematol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>92</volume>
            <issue>3</issue>
            <fpage>425</fpage>
            <page-range>425-31</page-range>
            <pub-id pub-id-type="pmid">20848343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guernsey</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Campagna</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kellogg</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lachance</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nightingale</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rideout</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saint-Amant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Orr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bottomley</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Ludman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dyack</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia.</article-title>
            <source>Nat Genet</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>651</fpage>
            <page-range>651-3</page-range>
            <pub-id pub-id-type="pmid">19412178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>OP</given-names>
              </name>
              <name>
                <surname>Hann</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Brockington</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pearson's marrow/pancreas syndrome: haematological features associated with deletion and duplication of mitochondrial DNA.</article-title>
            <source>Br J Haematol</source>
            <year>1995</year>
            <month>Jun</month>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>469</fpage>
            <page-range>469-72</page-range>
            <pub-id pub-id-type="pmid">7794775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearson</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Lobel</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kocoshis</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Naiman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Windmiller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lammi</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marsh</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction.</article-title>
            <source>J Pediatr</source>
            <year>1979</year>
            <month>Dec</month>
            <volume>95</volume>
            <issue>6</issue>
            <fpage>976</fpage>
            <page-range>976-84</page-range>
            <pub-id pub-id-type="pmid">501502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torraco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verrigni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gelmetti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Niceta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Montanari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rizza</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Diodato</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Di Nottia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lucarelli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sorrentino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Piemonte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Francisci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tartaglia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Dionisi-Vici</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Christodoulou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bertini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carrozzo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A novel mutation in NDUFB11 unveils a new clinical phenotype associated with lactic acidosis and sideroblastic anemia.</article-title>
            <source>Clin Genet</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>91</volume>
            <issue>3</issue>
            <fpage>441</fpage>
            <page-range>441-447</page-range>
            <pub-id pub-id-type="pmid">27102574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angelucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barosi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Camaschella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cappellini</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galanello</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marchetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tura</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.</article-title>
            <source>Haematologica</source>
            <year>2008</year>
            <month>May</month>
            <volume>93</volume>
            <issue>5</issue>
            <fpage>741</fpage>
            <page-range>741-52</page-range>
            <pub-id pub-id-type="pmid">18413891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bottomley</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Congenital sideroblastic anemias.</article-title>
            <source>Curr Hematol Rep</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-9</page-range>
            <pub-id pub-id-type="pmid">16537045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29019.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cotter</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Al-Sabah</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Fitzsimons</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis.</article-title>
            <source>Blood</source>
            <year>1999</year>
            <month>Mar</month>
            <day>01</day>
            <volume>93</volume>
            <issue>5</issue>
            <fpage>1757</fpage>
            <page-range>1757-69</page-range>
            <pub-id pub-id-type="pmid">10029606</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
